ATE350385T1 - Neue aryl fructose-1,6-bisphosphatase inhibitoren - Google Patents

Neue aryl fructose-1,6-bisphosphatase inhibitoren

Info

Publication number
ATE350385T1
ATE350385T1 AT01918456T AT01918456T ATE350385T1 AT E350385 T1 ATE350385 T1 AT E350385T1 AT 01918456 T AT01918456 T AT 01918456T AT 01918456 T AT01918456 T AT 01918456T AT E350385 T1 ATE350385 T1 AT E350385T1
Authority
AT
Austria
Prior art keywords
fructose
bisphosphatase inhibitors
new aryl
inhibitors
aryl
Prior art date
Application number
AT01918456T
Other languages
English (en)
Inventor
Brett C Bookser
Qun Dang
K Raja Reddy
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Application granted granted Critical
Publication of ATE350385T1 publication Critical patent/ATE350385T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826Acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01918456T 2000-03-08 2001-03-07 Neue aryl fructose-1,6-bisphosphatase inhibitoren ATE350385T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18775000P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
ATE350385T1 true ATE350385T1 (de) 2007-01-15

Family

ID=22690309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01918456T ATE350385T1 (de) 2000-03-08 2001-03-07 Neue aryl fructose-1,6-bisphosphatase inhibitoren

Country Status (20)

Country Link
US (2) US6919322B2 (de)
EP (2) EP1607401A1 (de)
JP (1) JP2003525944A (de)
KR (1) KR20020079988A (de)
CN (2) CN1516705A (de)
AT (1) ATE350385T1 (de)
AU (2) AU2001245532B2 (de)
BR (1) BR0109062A (de)
CA (1) CA2401706A1 (de)
CZ (1) CZ20023018A3 (de)
DE (1) DE60125734T2 (de)
HU (1) HUP0300344A3 (de)
IL (2) IL151248A0 (de)
MX (1) MXPA02008722A (de)
NO (1) NO20024240L (de)
PL (1) PL357251A1 (de)
RU (1) RU2002126616A (de)
SK (1) SK12722002A3 (de)
WO (1) WO2001066553A2 (de)
ZA (1) ZA200207004B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
US6756360B1 (en) * 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
MXPA02006156A (es) * 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
AU2001245532B2 (en) * 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
WO2004009118A1 (ja) * 2002-07-23 2004-01-29 Sankyo Company, Limited 糖尿病の発症予防薬
FR2846327B1 (fr) * 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
JP2008510018A (ja) * 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質
US20070259928A1 (en) * 2004-12-13 2007-11-08 Taishi Yoshida Medicinal Composition for Treating Diabetes
EP1825854A1 (de) * 2004-12-15 2007-08-29 Daiichi Sankyo Company, Limited EINEN FBPase INHIBITOR ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNG
EP1752450A1 (de) 2005-08-01 2007-02-14 Merck Sante Imidazolderivate als Fruktose-1,6-biphosphataseinhibitoren und pharmazeutische Zusammensetzungen diese enthaltend
CA2695583A1 (en) 2007-08-13 2009-02-19 Metabasis Therapeutics, Inc. Novel activators of glucokinase
EP2058308A1 (de) 2007-11-12 2009-05-13 Merck Sante Benzimidazoldihydrothiadiazinonderivate als Fructose-1,6-biphosphatase-Hemmer und diese enthaltende pharmazeutische Zusammensetzungen.
DK3366686T3 (da) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
US9006568B2 (en) * 2012-02-15 2015-04-14 Phillips 66 Company Synthesis of photovoltaic conjugated polymers
CN104428294B (zh) 2012-04-20 2017-07-14 拜尔农科股份公司 N‑环烷基‑n‑[(杂环基苯基)亚甲基]‑(硫代)羧酰胺衍生物
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
WO2014088795A1 (en) 2012-12-03 2014-06-12 Phillips 66 Company Benzo [1,2-b:4,5-b'] dithiophene-thienothiophene based conjugated polymers
EP3078378B1 (de) 2015-04-08 2020-06-24 Vaiomer Verwendung von faktor-xa-inhibitoren zur regulierung von glykämie
US9905769B2 (en) 2015-10-01 2018-02-27 Phillips 66 Company Process of manufacturing an electron transport material
US9911919B2 (en) 2015-10-01 2018-03-06 Phillips 66 Company Process of manufacturing an electron transport material
US10418555B2 (en) 2015-10-01 2019-09-17 Phillips 66 Company Formation of films for organic photovoltaics
US10312448B2 (en) 2015-10-01 2019-06-04 Phillips 66 Company Process of manufacturing an electron transport material
US10099963B2 (en) 2015-10-01 2018-10-16 Phillips 66 Company Formation of films for organic photovoltaics
WO2018017910A1 (en) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CN111116647B (zh) * 2019-12-02 2021-08-24 西安电子科技大学 一种具有hdac抑制活性的磷酸类化合物及其制备方法与用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL72851C (de) * 1950-10-31 1900-01-01
US2683168A (en) * 1950-12-22 1954-07-06 California Research Corp Preparation of organo phosphonyl chlorides
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
GB2043073B (en) * 1979-02-13 1983-05-11 Symphar Sa Mono-and diphosphonate compounds
US4640701A (en) * 1984-04-17 1987-02-03 Ciba-Geigy Corporation Herbicidal phosphonic acid and phosphinic acid derivatives
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0243173B1 (de) * 1986-04-24 1991-06-26 Fujisawa Pharmaceutical Co., Ltd. Diphosphonsäure-Verbindungen, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US5091552A (en) 1986-06-30 1992-02-25 Board Of Regents, The University Of Texas System Novel antitumor aldophosphamide analogs
US5045557A (en) * 1987-03-20 1991-09-03 Schering Agrochemicals Ltd. Imidazable fungicides and use thereof
US4943629A (en) 1988-08-12 1990-07-24 American Cyanamid Company Antidiabetic alpha-substituted phosphonates
US4968790A (en) 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
JPH03504728A (ja) 1989-01-24 1991-10-17 ジェンシア・ファーマシュウティカルズ,インコーポレイテッド Aicaリボシドの放出および血液グルコースの低減のための化合物および方法
EP0533833B1 (de) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorylierte prodrugs
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
US5208235A (en) * 1992-03-10 1993-05-04 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole derivatives
US5278153A (en) * 1992-05-18 1994-01-11 E. R. Squibb & Sons, Inc. Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
WO1994007867A1 (en) 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
CA2126601A1 (en) 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
WO1995007920A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Nucleotide analogs
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
JP4741725B2 (ja) 1998-03-06 2011-08-10 メタベイシス・セラピューティクス・インコーポレーテッド リン含有化合物のための新規なプロドラッグ
CA2289621A1 (en) 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
DE69910045T2 (de) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
DE19843383A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
ID30237A (id) 1998-12-24 2001-11-15 Metabasis Therapeutics Inc KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HK1043796B (en) 1999-03-05 2007-02-23 Metabasis Therapeutics, Inc. Novel phosphorus-containing prodrugs
MXPA02006156A (es) 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
EP1741445B1 (de) 2000-01-21 2013-08-14 Novartis AG Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
AU2001245532B2 (en) 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PL365779A1 (en) 2000-07-06 2005-01-10 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
JP2008510018A (ja) 2004-08-18 2008-04-03 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−1,6−ビスホスファターゼの新規チアゾール阻害物質

Also Published As

Publication number Publication date
SK12722002A3 (sk) 2003-04-01
CN1699383A (zh) 2005-11-23
WO2001066553A3 (en) 2002-03-14
NO20024240L (no) 2002-11-08
IL151248A (en) 2007-06-17
EP1265907B9 (de) 2007-05-09
KR20020079988A (ko) 2002-10-21
IL151248A0 (en) 2003-04-10
ZA200207004B (en) 2003-12-01
HUP0300344A2 (hu) 2003-06-28
HUP0300344A3 (en) 2007-05-29
EP1265907A2 (de) 2002-12-18
US20020040014A1 (en) 2002-04-04
CA2401706A1 (en) 2001-09-13
PL357251A1 (en) 2004-07-26
WO2001066553A2 (en) 2001-09-13
AU2001245532B2 (en) 2005-08-11
US7371739B2 (en) 2008-05-13
JP2003525944A (ja) 2003-09-02
US6919322B2 (en) 2005-07-19
HK1051865A1 (en) 2003-08-22
EP1607401A1 (de) 2005-12-21
DE60125734D1 (en) 2007-02-15
DE60125734T2 (de) 2007-10-25
AU4553201A (en) 2001-09-17
MXPA02008722A (es) 2004-05-05
BR0109062A (pt) 2002-11-26
CZ20023018A3 (cs) 2003-01-15
EP1265907B1 (de) 2007-01-03
CN1516705A (zh) 2004-07-28
RU2002126616A (ru) 2004-03-20
US20050176684A1 (en) 2005-08-11
NO20024240D0 (no) 2002-09-05

Similar Documents

Publication Publication Date Title
ATE350385T1 (de) Neue aryl fructose-1,6-bisphosphatase inhibitoren
DK1112275T3 (da) Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
WO2001047935A3 (en) Novel bisamidate phosphonate prodrugs
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE60231295D1 (de) R und ppar modulatoren
GB0213612D0 (en) Organic compounds
PT1349856E (pt) Compostos de isoindolina-1-ona activadores da glicocinase
TR200100805T2 (tr) Tetrahidropiridoeterler
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
ATE449066T1 (de) Biguanidderivate
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
WO2004053107A3 (en) Methods for treating diabetes
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
DK1366033T3 (da) Kemiske forbindelser
AP2248A (en) Treatment of HI-virus infections with oxidised blood proteins.
SE0102385D0 (sv) Screening methods
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties